Korro Bio (NASDAQ:KRRO – Get Free Report) and Organogenesis (NASDAQ:ORGO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.
Risk & Volatility
Korro Bio has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Korro Bio and Organogenesis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Korro Bio | 1 | 0 | 5 | 2 | 3.00 |
| Organogenesis | 1 | 1 | 2 | 0 | 2.25 |
Valuation and Earnings
This table compares Korro Bio and Organogenesis”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Korro Bio | $6.28 million | 56.73 | -$83.58 million | ($9.75) | -3.89 |
| Organogenesis | $429.31 million | 1.23 | $860,000.00 | ($0.14) | -29.75 |
Organogenesis has higher revenue and earnings than Korro Bio. Organogenesis is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Korro Bio and Organogenesis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Korro Bio | N/A | -61.51% | -42.87% |
| Organogenesis | -1.92% | -0.37% | -0.20% |
Insider & Institutional Ownership
13.2% of Korro Bio shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 4.6% of Korro Bio shares are held by insiders. Comparatively, 33.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Korro Bio beats Organogenesis on 8 of the 15 factors compared between the two stocks.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Organogenesis
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
